NCT06299826
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure
AstraZeneca·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Chronic Heart Failure
- Drug/Device/Intervention
- AZD5462
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- AstraZeneca
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Jun 10, 2024
- End date
- Nov 24, 2025
- Enrollment
- 360 participants
Primary outcome
Cohort A and B: Change from Baseline in Ejection Fraction
Summary
The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in
 participants with chronic heart failure (HF).
ICD-10 classifications
Heart failureHeart failure, unspecifiedCongestive heart failureHypertensive heart disease with (congestive) heart failureHypertensive heart disease without (congestive) heart failure
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06299826
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06299826 through Pure Global AI's free database. This Phase 2 trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Chronic Heart Failure. Target enrollment is 360 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.